Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2006-09-05
2006-09-05
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S093400, C424S093200, C424S234100
Reexamination Certificate
active
07101558
ABSTRACT:
The present invention provides a vaccine production strain ofBordetella bronchisepticathat produces a pertussis toxin in high yield. The present invention provides a method for creating aBordetella bronchisepticacell line which produces aBordetella pertussistoxin comprising the steps of introducing a plasmid containing a DNA encoding antibiotic resistance into aBordetella bronchisepticastrain, selecting for isolates in which the DNA encoding antibiotic resistance is recombinantly incorporated into the chromosome in place of theBordetella bronchisepticatoxin gene, introducing a plasmid containing DNA encoding subunits of theBordetella pertussistoxins into theBordetella bronchisepticaisolates; and, selecting for isolates in which DNA encodingBordetella pertussistoxin subunit is recombinantly incorporated into the chromosome, the resulting cells producing theBordetella pertussistoxin. The present invention further provides a method for creating aBordetella bronchisepticacell line which produces aBordetella pertussistoxin and does not express filamentous hemagglutinin.
REFERENCES:
patent: 5643747 (1997-07-01), Baker et al.
patent: 5705361 (1998-01-01), Walker et al.
patent: 0396964 (1989-10-01), None
Walker et al. Infect. Immun. 59: 4238-4248, 1991.
Lee et al. Infect. Immun. 57: 1413-1418, 1989.
Martinez et al. Mol. Microbiol. 22: 895-908, 1996.
Giardina et al. J. Bacteriol. 177: 6058-6063, 1995.
Burnette et al. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.Science.242:72-74. (1988).
Cieplak et al. Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant.Proceedings of the National Academy of Sciences of the U.S.A.85:4667-4671 (1988).
Cotter et al. Filamentous hemagglutinin ofBordetella bronchisepticais required for efficient establishment of tracheal colonization.Infect. Immun.66(12):5921-5929. (1998).
Lobet et al. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.Journal of Experimental Medicine.177:79-87. (1993).
Pizza et al. Mutants of pertussis toxin suitable for vaccine development.Science.246:497-500. (1989).
Suarez et al. Stable expression of pertussis toxin inBordetella bronchisepticaunder the control of a tightly regulated promoter.Applied and Environmental Microbiology.63(1):122-127. (1997).
Keith Jerry M.
Merkel Tod J.
Yang Xiaoming
Devi S.
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
High yield pertussis vaccine production strain and method... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High yield pertussis vaccine production strain and method..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High yield pertussis vaccine production strain and method... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556588